Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

C5 Antikörper

C5 Reaktivität: Human WB, IHC (fro), EIA Wirt: Maus Monoclonal HCC5-1 unconjugated
Produktnummer ABIN112155
  • Target Alle C5 Antikörper anzeigen
    C5 (Complement Component 5 (C5))
    Reaktivität
    • 125
    • 32
    • 19
    • 16
    • 2
    • 2
    • 2
    Human
    Wirt
    • 113
    • 16
    • 6
    • 4
    Maus
    Klonalität
    • 123
    • 15
    Monoklonal
    Konjugat
    • 49
    • 13
    • 13
    • 9
    • 5
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 1
    Dieser C5 Antikörper ist unkonjugiert
    Applikation
    • 69
    • 50
    • 42
    • 39
    • 26
    • 20
    • 12
    • 9
    • 7
    • 7
    • 5
    • 5
    • 5
    • 4
    • 4
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)
    Spezifität
    HCC5.1 allows detection of native complement component C5 and discrimination from activated C5b-9 complexes, especially in different forms of glomerulonephritis. This HCC5.1 antibody reacts with both native C5 as well as with C5b. Native C5 is only detected with HCC5.1, while C5b is detected by both HCC5.1 and HCC5.2. Polypeptide Reacting: Mr 200,000 polypeptide of native complement component C5.Polypeptide Reacting
    Kreuzreaktivität (Details)
    Species reactivity (tested):Human.
    Aufreinigung
    Affinity Chromatography on Protein A
    Immunogen
    Human complement component C5
    Klon
    HCC5-1
    Isotyp
    IgG1
    Top Product
    Discover our top product C5 Primärantikörper
  • Applikationshinweise
    Immunohistochemistry on frozen sections: 1: 10, 1h at RT. Western Blot. ELISA.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Rekonstitution
    Restore with 1 mL distilled water
    Buffer
    PBS, pH 7.4, 0.09 % Sodium Azide, 0.5 % BSA
    Vorsichtsmaßnahmen
    Use of sodium azide as a preservative will substantially inhibit the enzyme activity of horseradish peroxidase.
    Handhabung
    Avoid repeated freezing and thawing.
    Lagerung
    4 °C/-20 °C
    Informationen zur Lagerung
    Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
  • Target
    C5 (Complement Component 5 (C5))
    Andere Bezeichnung
    Complement C5 (C5 Produkte)
    Synonyme
    C5 antikoerper, LOC565774 antikoerper, C5a antikoerper, C5b antikoerper, CPAMD4 antikoerper, Hc antikoerper, RGD1561905 antikoerper, He antikoerper, complement C5 antikoerper, complement component 5 antikoerper, hemolytic complement antikoerper, C5 antikoerper, c5 antikoerper, Hc antikoerper
    Hintergrund
    The complement system is composed of over 30 proteins, activated in response to tissue injury, invading pathogens or other foreign surfaces. The complement pathways can be divided in the activation pathways and lytic pathway. The activation pathways lead via C3 to the cleavage of the fifth complement component C5 into C5a and C5b, resulting in activation of the lytic pahway C5a was first described as a cleavage product of C5 with chemotactic and anaphylatoxic properties. Further characterization revealed that C5a is an essential part of the innate immune response and evidence now suggests that it may also play a role in adaptive immunity. Complement fragment C5a is a 74 residue pro-inflammatory polypeptide. C5a induces smooth muscle contraction, increases vascular permeability, causes degranulation of mast cells and basophils, and release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. C5a binds to at least two seven-transmembrane domain receptors, C5aR (C5R1, CD88) and C5L2 (gpr77), expressed ubiquitously on a wide variety of cells but particularly on the surface of immune cells like macrophages, neutrophils and T cells. The former is a well-established receptor that initiates G-protein-coupled signaling via mitogen-activated protein kinase pathways, thereby by inducing synthesis of cytokines such as TNF-alpha, IL-1beta, IL-6 and IL-8. Its in vivo blockade greatly reduces inflammatory injury. Much less is known about C5L2, occupancy of which by C5a does not initiate increased intracellular Ca(2+).The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases. Nowadays C5a is also implicated in non-immunological functions associated with developmental biology, CNS development and neurodegeneration, tissue regeneration, and haematopoiesis. C5 is synthesised in the liver as a single polypeptide chain. Before secretion the molecule is glycosylated and secreted into plasma as a 190 kDa glycoprotein consisting of a disulphide linked alpha-chain (111 kDa) and beta-chain (75 kDa). C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain).Synonyms: C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, CPAMD4, Complement component 5
    Gen-ID
    727
    NCBI Accession
    NP_001726
    UniProt
    P01031
    Pathways
    Komplementsystem, Carbohydrate Homeostasis
Sie sind hier:
Kundenservice